Oroxylin A (OA), a novel CDK9 inhibitor, showed strong therapeutic potential against HCC and a striking capacity to overcome drug resistance by downregulating PINK1-PRKN-mediated mitophagy. This evidence concerns the gene PRKN and hepatocellular carcinoma.